Vyant Bio, Inc. financial data

Industry
Services-Medical Laboratories
Location
2370 State Route 70 West, Suite 310, Cherry Hill,, NJ
State of incorporation
DE
Fiscal year end
December 31
Former names
CANCER GENETICS, INC (to 3/31/2021), CANCER GENETICS INC (to 11/1/2010)
Latest financial report
10-K - Q4 2022 - Mar 31, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 238 % -53.8%
Quick Ratio 4.16 % -47.2%
Debt-to-equity 55.1 % +357%
Return On Equity -144 % -86.4%
Return On Assets -93 % -34.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.27M shares -78.4%
Common Stock, Shares, Outstanding 5.92M shares +2.14%
Entity Public Float 24.7M USD -69.4%
Common Stock, Value, Issued 1K USD 0%
Weighted Average Number of Shares Outstanding, Basic 5.87M shares +29.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 666K USD -42%
Research and Development Expense 6.77M USD +58.5%
Selling and Marketing Expense 8.8M USD +4.44%
Operating Income (Loss) -15.9M USD -1.31%
Nonoperating Income (Expense) 105K USD -6.76%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -15.8M USD +14.9%
Net Income (Loss) Attributable to Parent -22.7M USD +44.5%
Earnings Per Share, Basic -3.87 USD/shares +57.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 10M USD -51.3%
Inventory, Net 53K USD -88.8%
Assets, Current 11.5M USD -50.4%
Property, Plant and Equipment, Net 1.11M USD +8.43%
Operating Lease, Right-of-Use Asset 1.54M USD +129%
Assets 15.2M USD -59.6%
Accounts Payable, Current 655K USD -11.5%
Accrued Liabilities, Current 1.15M USD +51%
Contract with Customer, Liability, Current 72K USD -2.7%
Liabilities, Current 3.67M USD -32.5%
Operating Lease, Liability, Noncurrent 1.3M USD +152%
Liabilities 5.3M USD -16.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax -32K USD +56.8%
Retained Earnings (Accumulated Deficit) -102M USD -28.8%
Stockholders' Equity Attributable to Parent 9.91M USD -68.3%
Liabilities and Equity 15.2M USD -59.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.97M USD +13.4%
Net Cash Provided by (Used in) Financing Activities -136K USD -102%
Net Cash Provided by (Used in) Investing Activities -60K USD -100%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 5.92M shares +2.14%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -4.17M USD -113%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 16.4M USD -50.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 7K USD
Deferred Tax Assets, Valuation Allowance 25.6M USD +17.5%
Deferred Tax Assets, Gross 26M USD +18.3%
Operating Lease, Liability 1.61M USD +134%
Depreciation 522K USD -5.09%
Payments to Acquire Property, Plant, and Equipment 30K USD +15.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -22.6M USD +44.7%
Lessee, Operating Lease, Liability, to be Paid 1.94M USD +123%
Property, Plant and Equipment, Gross 3.58M USD +19.7%
Operating Lease, Liability, Current 313K USD +79.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 423K USD +169%
Lessee, Operating Lease, Liability, to be Paid, Year One 433K USD +89.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure -20.2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 325K USD +80.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 427K USD +214%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 9.76M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 441K USD +237%
Additional Paid in Capital 111M USD +1.15%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 401K USD +120%
Share-based Payment Arrangement, Expense 305K USD +140%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%